KR102478614B1 - 염증 질환의 치료를 위한 신규의 염 및 그의 약학 조성물 - Google Patents

염증 질환의 치료를 위한 신규의 염 및 그의 약학 조성물 Download PDF

Info

Publication number
KR102478614B1
KR102478614B1 KR1020167023807A KR20167023807A KR102478614B1 KR 102478614 B1 KR102478614 B1 KR 102478614B1 KR 1020167023807 A KR1020167023807 A KR 1020167023807A KR 20167023807 A KR20167023807 A KR 20167023807A KR 102478614 B1 KR102478614 B1 KR 102478614B1
Authority
KR
South Korea
Prior art keywords
salt
compound
present
disease
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167023807A
Other languages
English (en)
Korean (ko)
Other versions
KR20160110518A (ko
Inventor
니콜라스 룩 사부르라울트
칼라 드 페버리
아마드 셰이크
Original Assignee
갈라파고스 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 갈라파고스 엔.브이. filed Critical 갈라파고스 엔.브이.
Publication of KR20160110518A publication Critical patent/KR20160110518A/ko
Application granted granted Critical
Publication of KR102478614B1 publication Critical patent/KR102478614B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L63/00—Network architectures or network communication protocols for network security
    • H04L63/04—Network architectures or network communication protocols for network security for providing a confidential data exchange among entities communicating through data packet networks
    • H04L63/0428—Network architectures or network communication protocols for network security for providing a confidential data exchange among entities communicating through data packet networks wherein the data content is protected, e.g. by encrypting or encapsulating the payload
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L63/00—Network architectures or network communication protocols for network security
    • H04L63/06—Network architectures or network communication protocols for network security for supporting key management in a packet data network
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L63/00—Network architectures or network communication protocols for network security
    • H04L63/08—Network architectures or network communication protocols for network security for authentication of entities
    • H04L63/0861—Network architectures or network communication protocols for network security for authentication of entities using biometrical features, e.g. fingerprint, retina-scan
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L63/00—Network architectures or network communication protocols for network security
    • H04L63/20—Network architectures or network communication protocols for network security for managing network security; network security policies in general
    • H04L63/205—Network architectures or network communication protocols for network security for managing network security; network security policies in general involving negotiation or determination of the one or more network security mechanisms to be used, e.g. by negotiation between the client and the server or between peers or by selection according to the capabilities of the entities involved
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L67/00—Network arrangements or protocols for supporting network services or applications
    • H04L67/01—Protocols
    • H04L67/10—Protocols in which an application is distributed across nodes in the network
    • H04L67/104—Peer-to-peer [P2P] networks
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L67/00—Network arrangements or protocols for supporting network services or applications
    • H04L67/50—Network services
    • H04L67/51—Discovery or management thereof, e.g. service location protocol [SLP] or web services
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/80—Services using short range communication, e.g. near-field communication [NFC], radio-frequency identification [RFID] or low energy communication
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W8/00—Network data management
    • H04W8/22—Processing or transfer of terminal data, e.g. status or physical capabilities
    • H04W8/24—Transfer of terminal data
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W92/00—Interfaces specially adapted for wireless communication networks
    • H04W92/16—Interfaces between hierarchically similar devices
    • H04W92/18—Interfaces between hierarchically similar devices between terminal devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Computer Security & Cryptography (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Computing Systems (AREA)
  • Computer Hardware Design (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Databases & Information Systems (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020167023807A 2014-02-07 2015-02-04 염증 질환의 치료를 위한 신규의 염 및 그의 약학 조성물 Active KR102478614B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1402071.3A GB201402071D0 (en) 2014-02-07 2014-02-07 Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB1402071.3 2014-02-07
PCT/EP2015/052242 WO2015117981A1 (en) 2014-02-07 2015-02-04 Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (2)

Publication Number Publication Date
KR20160110518A KR20160110518A (ko) 2016-09-21
KR102478614B1 true KR102478614B1 (ko) 2022-12-16

Family

ID=50390572

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167023807A Active KR102478614B1 (ko) 2014-02-07 2015-02-04 염증 질환의 치료를 위한 신규의 염 및 그의 약학 조성물

Country Status (28)

Country Link
US (7) US9382247B2 (cg-RX-API-DMAC7.html)
EP (2) EP3842432A1 (cg-RX-API-DMAC7.html)
JP (2) JP2017505329A (cg-RX-API-DMAC7.html)
KR (1) KR102478614B1 (cg-RX-API-DMAC7.html)
CN (2) CN111499630A (cg-RX-API-DMAC7.html)
AR (1) AR099307A1 (cg-RX-API-DMAC7.html)
AU (4) AU2015215045B2 (cg-RX-API-DMAC7.html)
CA (1) CA2938219C (cg-RX-API-DMAC7.html)
CY (1) CY1124349T1 (cg-RX-API-DMAC7.html)
DK (1) DK3102575T3 (cg-RX-API-DMAC7.html)
EA (2) EA032596B1 (cg-RX-API-DMAC7.html)
ES (1) ES2853375T3 (cg-RX-API-DMAC7.html)
GB (1) GB201402071D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20210194T1 (cg-RX-API-DMAC7.html)
HU (1) HUE053309T2 (cg-RX-API-DMAC7.html)
IL (1) IL246833B (cg-RX-API-DMAC7.html)
LT (1) LT3102575T (cg-RX-API-DMAC7.html)
MX (2) MX395415B (cg-RX-API-DMAC7.html)
NZ (1) NZ722603A (cg-RX-API-DMAC7.html)
PL (1) PL3102575T3 (cg-RX-API-DMAC7.html)
PT (1) PT3102575T (cg-RX-API-DMAC7.html)
RS (1) RS61450B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201606433PA (cg-RX-API-DMAC7.html)
SI (1) SI3102575T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100060T1 (cg-RX-API-DMAC7.html)
TW (2) TWI767878B (cg-RX-API-DMAC7.html)
UY (1) UY35984A (cg-RX-API-DMAC7.html)
WO (1) WO2015117981A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402071D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201402070D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
MX386902B (es) * 2015-04-13 2025-03-19 Alfasigma Spa Metodos para el tratamiento de trastornos cardiovasculares.
BR112017021583A2 (pt) * 2015-04-13 2018-07-03 Galapagos Nv métodos para o tratamento de transtornos inflamatórios
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
CN105198876B (zh) * 2015-09-18 2017-09-29 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物h晶型及其制备方法
CN105198880B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物a晶型及其制备方法
CN105198878B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物f晶型及其制备方法
CN105198879B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物c晶型及其制备方法
CN105198877B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物g晶型及其制备方法
CN105111206B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物e晶型及其制备方法
CN105218539B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物b晶型及其制备方法
CN105111207B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物d晶型及其制备方法
US20170174788A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
US20170173034A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
WO2017106568A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer
CN105669669A (zh) * 2016-03-04 2016-06-15 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物的a晶型、b晶型、d晶型、g晶型和m晶型及其制备方法
MX2018011422A (es) * 2016-03-21 2019-07-08 Crystal Pharmatech Co Ltd Farmaco de sal cristalina de clorhidrato para tratar o prevenir enfermedad asociada con janus cinasas (jak) y su metodo de preparacion.
CN109476662A (zh) * 2016-08-03 2019-03-15 苏州科睿思制药有限公司 一种jak1选择性抑制剂的新晶型及其制备方法和用途
CA3043396A1 (en) 2016-11-10 2018-05-17 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
GB201702603D0 (en) 2017-02-17 2017-04-05 Galápagos Nv Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JOP20180018A1 (ar) * 2017-03-14 2019-01-30 Gilead Sciences Inc تركيبات صيدلية تتضمن مثبط jak
GB201808575D0 (en) 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits
US10815227B2 (en) 2018-08-27 2020-10-27 Cadila Healthcare Limited Processes for the preparation of filgotinib
WO2020092245A1 (en) * 2018-10-29 2020-05-07 Zorday IP, LLC Network-enabled electronic cigarette
WO2020177705A1 (zh) * 2019-03-05 2020-09-10 苏州科睿思制药有限公司 Filgotinib的马来酸盐晶型CSI及其制备方法和用途
BR112021019087A2 (pt) * 2019-03-30 2021-11-30 Unichem Lab Ltd Novo processo para a preparação de filgotinibe e intermediários do mesmo
WO2021044327A1 (en) * 2019-09-03 2021-03-11 Dr. Reddy's Laboratories Limited Solid forms of filgotinib maleate and processes thereof
CN114075188A (zh) * 2020-08-11 2022-02-22 南京柯菲平盛辉制药有限公司 芳香杂环酰胺类化合物及其制备方法和医药用途
JP2023553956A (ja) * 2020-12-09 2023-12-26 セルバトゥス リミテッド 関節の炎症性障害のための併用療法
CN113773322B (zh) * 2021-11-10 2022-02-11 奥锐特药业(天津)有限公司 一种Filgotinib的制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
WO2010149769A1 (en) * 2009-06-26 2010-12-29 Galapagos Nv 5-phenyl-[1,2,4 ]triazolo[1,5-a]pyridin-2-yl carboxamides as jak inhibitors
WO2011036895A1 (ja) 2009-09-25 2011-03-31 杏林製薬株式会社 マレイン酸塩およびその結晶
CN102105471A (zh) 2008-07-25 2011-06-22 加拉帕戈斯股份有限公司 用于治疗变性和炎性疾病的新化合物
JP2013049632A (ja) * 2011-08-30 2013-03-14 Kowa Co ベンゾチアジン化合物のモノマレイン酸塩を有効成分とするアレルギー疾患の予防及び／又は治療剤
JP2013518828A (ja) 2010-02-04 2013-05-23 チャンスー ヘンルイ メディシン カンパニー リミテッド ピロロ窒素複素環誘導体の薬学的に許容される塩、その調製法、および医学的使用
WO2013189771A1 (en) 2012-06-22 2013-12-27 Galapagos Nv Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2549632B2 (ja) * 1986-08-20 1996-10-30 三井石油化学工業株式会社 オレフインの重合方法
WO2000044722A1 (en) 1999-01-29 2000-08-03 Chugai Seiyaku Kabushiki Kaisha Chondrongenesis promotors and indolin-2-one derivatives
WO2002087620A1 (en) 2001-04-27 2002-11-07 Chugai Seiyaku Kabushiki Kaisha Chondrogenesis promoters
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
JPWO2004039816A1 (ja) * 2002-10-29 2006-03-02 塩野義製薬株式会社 セフェム化合物の無機酸塩の結晶
ATE334131T1 (de) 2003-02-14 2006-08-15 Pfizer Prod Inc Triazolopyridine als entzündungshemmende verbindungen
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
JP2008503712A (ja) 2004-06-21 2008-02-07 ガラパゴス・ナムローゼ・フェンノートシャップ 骨関節炎治療の方法及び手段
MX2007002050A (es) 2004-08-18 2007-03-29 Pharmacia & Upjohn Co Llc Compuestos de triazolopiridina.
MX2007004179A (es) 2004-10-07 2007-06-07 Warner Lambert Co Derivados de triazolpiridina como agentes antibacterianos.
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
JP5336375B2 (ja) 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
TW200904816A (en) 2007-06-05 2009-02-01 Takeda Pharmaceutical Fused heterocycle derivatives and use thereof
MX2010000716A (es) 2007-07-18 2010-03-26 Novartis Ag Compuestos de heteroarilo biciclicos y su uso como inhibidores de cinasa.
MX2010002312A (es) 2007-08-31 2010-03-18 Merck Serono Sa Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP5595389B2 (ja) 2008-06-20 2014-09-24 ジェネンテック， インコーポレイテッド トリアゾロピリジンｊａｋ阻害剤化合物と方法
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
US20110124692A1 (en) * 2008-07-31 2011-05-26 Daiichi Sankyo Company, Limited Crystalline forms of thiazolidinedione compound and its manufacturing method
AU2010254806C1 (en) 2009-06-05 2016-07-07 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
SA112330992B1 (ar) 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
BR112017021583A2 (pt) 2015-04-13 2018-07-03 Galapagos Nv métodos para o tratamento de transtornos inflamatórios
MX386902B (es) 2015-04-13 2025-03-19 Alfasigma Spa Metodos para el tratamiento de trastornos cardiovasculares.
US20170173034A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
JOP20180018A1 (ar) 2017-03-14 2019-01-30 Gilead Sciences Inc تركيبات صيدلية تتضمن مثبط jak
GB201808575D0 (en) 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
CN102105471A (zh) 2008-07-25 2011-06-22 加拉帕戈斯股份有限公司 用于治疗变性和炎性疾病的新化合物
JP2011529032A (ja) 2008-07-25 2011-12-01 ガラパゴス・ナムローゼ・フェンノートシャップ 変性及び炎症性疾患の治療に有用な新規化合物
WO2010149769A1 (en) * 2009-06-26 2010-12-29 Galapagos Nv 5-phenyl-[1,2,4 ]triazolo[1,5-a]pyridin-2-yl carboxamides as jak inhibitors
JP2012530766A (ja) 2009-06-26 2012-12-06 ガラパゴス・ナムローゼ・フェンノートシャップ ＪＡＫ阻害剤としての５−フェニル−［１，２，４］トリアゾロ［１，５−ａ］ピリジン−２−イルカルボキサミド
WO2011036895A1 (ja) 2009-09-25 2011-03-31 杏林製薬株式会社 マレイン酸塩およびその結晶
JP2013518828A (ja) 2010-02-04 2013-05-23 チャンスー ヘンルイ メディシン カンパニー リミテッド ピロロ窒素複素環誘導体の薬学的に許容される塩、その調製法、および医学的使用
JP2013049632A (ja) * 2011-08-30 2013-03-14 Kowa Co ベンゾチアジン化合物のモノマレイン酸塩を有効成分とするアレルギー疾患の予防及び／又は治療剤
WO2013189771A1 (en) 2012-06-22 2013-12-27 Galapagos Nv Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
AU2022235624A1 (en) 2022-10-20
IL246833A0 (en) 2016-08-31
CA2938219C (en) 2023-01-24
CN105960407A (zh) 2016-09-21
EA032596B1 (ru) 2019-06-28
EA201691584A1 (ru) 2017-01-30
US10708263B2 (en) 2020-07-07
AR099307A1 (es) 2016-07-13
AU2019202441A1 (en) 2019-05-02
CA2938219A1 (en) 2015-08-13
EP3102575B1 (en) 2021-01-13
MX395415B (es) 2025-03-19
AU2015215045A1 (en) 2016-08-11
TWI792593B (zh) 2023-02-11
HRP20210194T1 (hr) 2021-03-19
PL3102575T3 (pl) 2021-07-26
TW202229274A (zh) 2022-08-01
MX2016010068A (es) 2016-11-15
GB201402071D0 (en) 2014-03-26
PT3102575T (pt) 2021-02-04
US20230406857A1 (en) 2023-12-21
US20150225398A1 (en) 2015-08-13
AU2015215045B2 (en) 2019-01-24
EP3102575A1 (en) 2016-12-14
US20210269435A1 (en) 2021-09-02
TW201613915A (en) 2016-04-16
US20250289816A1 (en) 2025-09-18
KR20160110518A (ko) 2016-09-21
SG11201606433PA (en) 2016-09-29
EP3842432A1 (en) 2021-06-30
US11667633B2 (en) 2023-06-06
SMT202100060T1 (it) 2021-03-15
WO2015117981A1 (en) 2015-08-13
IL246833B (en) 2022-07-01
JP2017505329A (ja) 2017-02-16
RS61450B1 (sr) 2021-03-31
UY35984A (es) 2015-09-30
US20180007043A1 (en) 2018-01-04
DK3102575T3 (da) 2021-02-08
LT3102575T (lt) 2021-04-26
AU2019202441B2 (en) 2020-08-06
TWI767878B (zh) 2022-06-21
CY1124349T1 (el) 2022-07-22
EA201990330A1 (ru) 2020-01-31
AU2020260391B2 (en) 2022-07-28
NZ722603A (en) 2019-07-26
JP2020097595A (ja) 2020-06-25
CN111499630A (zh) 2020-08-07
US20160376269A1 (en) 2016-12-29
AU2020260391A1 (en) 2020-11-19
US12234235B2 (en) 2025-02-25
SI3102575T1 (sl) 2021-04-30
AU2022235624B2 (en) 2023-11-23
US9382247B2 (en) 2016-07-05
US20200244651A1 (en) 2020-07-30
US10919890B2 (en) 2021-02-16
SG10202013187PA (en) 2021-02-25
MX376000B (es) 2025-03-07
ES2853375T3 (es) 2021-09-15
HUE053309T2 (hu) 2021-06-28
MX2020003368A (es) 2020-07-29

Similar Documents

Publication Publication Date Title
US12234235B2 (en) Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CN102482273B (zh) 作为jak抑制剂的5-苯基-[1,2,4]三唑并[1,5-a]吡啶-2-甲酰胺化合物
US10493158B2 (en) Pharmaceutical compositions for the treatment of inflammatory disorders
KR20200096571A (ko) 질병의 치료를 위한 신규 화합물 및 그의 약학 조성물
CN103492386A (zh) 可用于治疗变性和炎性疾病的新化合物
WO2017133423A1 (zh) 一种取代的吡啶酰胺类化合物及其应用
KR102511209B1 (ko) 벤즈이미다졸 유도체 및 염증 질환의 치료를 위한 그의 약학 조성물
HK1231859B (en) Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
HK1231859A1 (en) Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EA041895B1 (ru) Новые соли и их фармацевтические композиции для лечения воспалительных заболеваний

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4